BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+14.88%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$594M
AUM Growth
+$594M
(+17%)
Cap. Flow
+$21.6M
Cap. Flow
% of AUM
3.64%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
3
Reduced
–
Closed
–
Top Buys
| 1 |
IMPR
IMPRIVATA, INC COM
IMPR
|
$7.55M |
| 2 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$6.83M |
| 3 |
Lineage Cell Therapeutics
LCTX
|
$6.06M |
| 4 |
CYNO
Cynosure, Inc. Class A
CYNO
|
$961K |
| 5 |
STAAR Surgical
STAA
|
$210K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 46.96% |
| 2 | Consumer Staples | 40.13% |
| 3 | Technology | 1.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monster Beverage
MNST
$60.9B
| $238M | 40.13% | 1,599,136 | – | – |
|
|
MNK
2
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $121M | 20.37% | 1,619,968 | – | – |
|
|
3
Lineage Cell Therapeutics
LCTX
$267M
| $82.8M | 13.95% | 21,864,396 +1,600,000 | +8% | +$6.06M |
|
|
4
STAAR Surgical
STAA
$1.36B
| $61.7M | 10.4% | 8,646,923 +29,361 | +0.3% | +$210K |
|
|
CYNO
5
DELISTED
Cynosure, Inc. Class A
CYNO
| $41M | 6.9% | 916,975 +21,520 | +2% | +$961K |
|
6
iShares Russell 2000 ETF
IWM
$67B
| $28.2M | 4.74% | 250,000 | – | – |
|
|
IMPR
7
DELISTED
IMPRIVATA, INC COM
IMPR
| $7.55M | 1.27% | +668,526 | New | +$7.55M |
|
|
IMDX
8
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $6.83M | 1.15% | +1,093,219 | New | +$6.83M |
|
|
AST
9
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $6.45M | 1.09% | 1,641,025 | – | – |
|